Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

High Dimensional Clustering and Identification of Immune Cell Hybrid Populations in B-ALL across the Disease Continuum

Matthew Newman, Hong De Sa, Kaelan Byrd, Ranish Patel, Michael S. Parappilly, Yoko Kosaka, Evan F. Lind, Jessica T. Leonard

Blood (2023) 142 (Supplement 1): 5627.

https://doi.org/10.1182/blood-2023-180248

Published: 2023

Journal Articles

Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML

Bridget A Robinson, Philipp Sergeev, Yoko Kosaka, Thomas Jacob, Andy Kaempf, Evan F. Lind, Cristina Tognon, Luis A. Carvajal, Jorge F. DiMartino, Caroline A. Heckman, Tania Q Vu

Blood (2023) 142 (Supplement 1): 5037.

https://doi.org/10.1182/blood-2023-186506

Published: 2023

Journal Articles

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Blood (2023) 142 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2023-188311

Published: 2023

Journal Articles

The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Jennifer N. Saultz, Daniel Bottomly, Faith Burns, Kaelan Byrd, Yoko Kosaka, Shannon K. McWeeney, Stephen E. Kurtz, Guang Fan, Andy Kaempf, Karen McGovern, Lei Wang, Marta Sanchez-Martin, Dan S Kaufman, Evan F. Lind, Jeffrey W. Tyner

Blood (2022) 140 (Supplement 1): 3071–3072.

https://doi.org/10.1182/blood-2022-163166

Published: 2022

Journal Articles

Aryl Hydrocarbon Receptor (AHR) Gene Expression in AML Is Associated with FLT3-ITD+ AML and HLA-E Induced Immune Resistance Reversed By Ik-364

Jennifer N. Saultz, Evan F. Lind, Jeffrey W. Tyner, Kaelan Byrd, Shannon K. McWeeney, Yoko Kosaka, Karen McGovern, Lei Wang, Marta Sanchez-Martin

Blood (2021) 138 (Supplement 1): 1161.

https://doi.org/10.1182/blood-2021-147589

Published: 2021

Journal Articles

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph + ALL

Jessica T. Leonard, Yoko Kosaka, Pavani Malla, Dorian LaTocha, Adam Lamble, Brandon Hayes-Lattin, Kaelan Byrd, Brian J. Druker, Jeffrey W. Tyner, Bill H. Chang, Evan Lind

Blood (2021) 137 (7): 939–944.

https://doi.org/10.1182/blood.2020005655

Published: 2021

Journal Articles

Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness

Lauren K. Brady, PhD, David Soong, PhD, Evan F. Lind, PhD, Yoko Kosaka, PhD, Adam J. Lamble, MD, Michael Schaffer, PhD, Brendan P. Hodkinson, PhD, Clare Lefave, PhD, Ted Laderas, PhD, Shannon K. McWeeney, PhD, Homer Adams, III, PhD, Yann Abraham, PhD, Pegah Safabakhsh, MS, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Fei Huang, PhD

Blood (2018) 132 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2018-99-118424

Published: 2018

Journal Articles

T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia

Jessica Leonard, MD, Yoko Kosaka, PhD, Pavani Malla, MS, Brandon Hayes-Lattin, MD, Adam J. Lamble, MD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Bill H. Chang, MD PhD, Evan F. Lind, PhD

Blood (2018) 132 (Supplement 1): 2694.

https://doi.org/10.1182/blood-2018-99-119301

Published: 2018

Journal Articles

Altered T Cell Subsets and Function in Patients with Acute Lymphoblastic Leukemia

Jessica Leonard, MD, Yoko Kosaka, PhD, Matthew T Newman, BS, Adam J. Lamble, MD, Pavani Malla, MS, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Bill H. Chang, MD PhD, Evan F. Lind, PhD

Blood (2018) 132 (Supplement 1): 1547.

https://doi.org/10.1182/blood-2018-99-119409

Published: 2018

Journal Articles

Mass Cytometry As a Modality to Identify Candidates for Immune Checkpoint Inhibitor Therapy within Acute Myeloid Leukemia

Adam Lamble, MD, Yoko Kosaka, PhD, Fei Huang, A Kate Sasser, PhD, Homer Adams, III, PhD, Cristina E. Tognon, Ted Laderas, PhD, Shannon K. McWeeney, Marc M. Loriaux, Jeffrey W. Tyner, Brian J. Druker, MD, Evan F. Lind, PhD

Blood (2016) 128 (22): 2829.

https://doi.org/10.1182/blood.V128.22.2829.2829

Published: 2016

Journal Articles

Enhanced VISTA Expression in a Subset of Patients with Acute Myeloid Leukemia

Blood (2016) 128 (22): 4056.

https://doi.org/10.1182/blood.V128.22.4056.4056

Published: 2016

Journal Articles

Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia

Adam Lamble, MD, Yoko Kosaka, PhD, Pierrette Lo, MS, Fei Huang, PhD, Kate Sasser, PhD, Cristina E. Tognon, PhD, Marc Loriaux, MD PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Evan F. Lind, PhD

Blood (2015) 126 (23): 1374.

https://doi.org/10.1182/blood.V126.23.1374.1374

Published: 2015

Journal Articles

Efficacy of NK-92 Against Human Multiple Myeloma in a NOD/SCID Gamma Null Mouse Model

Brenna E. Swift, MASc, Brent A. Williams, MD, Yoko Kosaka, PhD, Joaquín Martínez-López, MD, Xinghua Wang, MD, Armand Keating, MD

Blood (2011) 118 (21): 1854.

https://doi.org/10.1182/blood.V118.21.1854.1854

Published: 2011

Journal Articles

Human Mesenchymal Stromal Cells (MSCs) Suppress Cytotoxicity of Natural Killer (NK) Cell Lines and Can Be Targets for NK-Mediated Cytolysis

Chia-Hsuan Donna Hu, Yoko Kosaka, Armand Keating, MD

Blood (2008) 112 (11): 2576.

https://doi.org/10.1182/blood.V112.11.2576.2576

Published: 2008

NARROW

High Dimensional Clustering and Identification of Immune Cell Hybrid Populations in B-ALL across the Disease Continuum

Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Aryl Hydrocarbon Receptor (AHR) Gene Expression in AML Is Associated with FLT3-ITD+ AML and HLA-E Induced Immune Resistance Reversed By Ik-364

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph + ALL

Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness

T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia

Altered T Cell Subsets and Function in Patients with Acute Lymphoblastic Leukemia

Mass Cytometry As a Modality to Identify Candidates for Immune Checkpoint Inhibitor Therapy within Acute Myeloid Leukemia

Enhanced VISTA Expression in a Subset of Patients with Acute Myeloid Leukemia

Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia

Efficacy of NK-92 Against Human Multiple Myeloma in a NOD/SCID Gamma Null Mouse Model

Human Mesenchymal Stromal Cells (MSCs) Suppress Cytotoxicity of Natural Killer (NK) Cell Lines and Can Be Targets for NK-Mediated Cytolysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only